Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-101 in Adults With Major Depressive Disorder
NCT07300969Phase 2Recruiting
- Sponsor
- Draig Therapeutics
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of DT-101 in major depressive disorder (MDD), sponsored by Draig Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
DT-101
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07300969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300969.